Hepatocellular Carcinoma, Survival Prediction Model, Atezolizumab and Bevacizumab, Overall Survival
G protein-coupled receptor autoantibodies, acute myocardial infarction, major adverse cardiovascular events, primary percutaneous coronary intervention, biomarkers